Exchange: NYSE·Updated 06:41 AM EDT
News
all
press releases
Ex-Div Reminder for McKesson (MCK)
Looking at the universe of stocks we cover at Dividend Channel, on 9/1/26, McKesson Corp (Symbol: MCK) will trade ex-dividend, for its quarterly dividend of $0.94, payable on 10/1/26. As a percentage of MCK's recent stock price of $893.81, this dividend works out to approximate...
Nasdaq News: Markets
More News
Here's How Much You Would Have Made Owning McKesson Stock In The Last 10 Years
McKesson (NYSE:MCK) has outperformed the market over the past 10 years by 3.54% on an annualized basis producing an average annual return of 17.04%. Currently, McKesson has a market capitalization of $103.82 billion.read more...
Benzinga
McKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Zacks
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
Zacks
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
McKesson will acquire Precision Medicine Group for $2.25 billion, expanding its clinical research and drug commercialization services.read more...
Benzinga
McKesson To Acquire Precision Medicine Group For $2.25 Bln
(RTTNews) - Tuesday, McKesson Corp. (MCK) announced an agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion...
Nasdaq News: Markets
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (Precision Medicine Group), a global provider of clinical research and biopharma commercialization services. McKesson will acquire Precision Medicine Group for...
Business Wire
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
Zacks
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
Zacks
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
Zacks

Advertisement|Remove ads.